Schneider Downs Wealth Management Advisors LP acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 8,078 shares of the biopharmaceutical company’s stock, valued at approximately $296,000.
Other hedge funds have also modified their holdings of the company. Capital World Investors grew its stake in shares of Pfizer by 19.1% during the 1st quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock valued at $7,337,737,000 after acquiring an additional 36,092,723 shares during the period. Nordea Investment Management AB lifted its holdings in Pfizer by 65.3% during the second quarter. Nordea Investment Management AB now owns 22,272,402 shares of the biopharmaceutical company’s stock valued at $719,176,000 after purchasing an additional 8,798,233 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Pfizer by 74.8% in the second quarter. Two Sigma Advisers LP now owns 11,066,501 shares of the biopharmaceutical company’s stock worth $361,875,000 after purchasing an additional 4,736,500 shares during the period. APG Asset Management N.V. increased its stake in shares of Pfizer by 129.4% in the first quarter. APG Asset Management N.V. now owns 6,955,829 shares of the biopharmaceutical company’s stock worth $227,038,000 after purchasing an additional 3,924,241 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Pfizer by 0.8% during the 2nd quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock valued at $13,980,372,000 after purchasing an additional 3,464,207 shares during the period. 69.08% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently weighed in on PFE shares. Mizuho reaffirmed a “buy” rating and issued a $43.00 target price on shares of Pfizer in a report on Tuesday, September 15th. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $44.00 to $39.00 in a research report on Monday, October 12th. SVB Leerink lifted their target price on Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a research note on Wednesday, July 29th. ValuEngine downgraded Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Finally, Royal Bank of Canada set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $39.64.
In related news, Director Ronald E. Blaylock acquired 13,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at $154,200. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.08% of the company’s stock.
PFE stock opened at $37.95 on Friday. The firm has a fifty day moving average price of $36.59 and a 200 day moving average price of $36.32. Pfizer Inc. has a fifty-two week low of $27.88 and a fifty-two week high of $40.97. The firm has a market cap of $210.88 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. The business had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business’s revenue was down 11.0% on a year-over-year basis. During the same period last year, the company posted $0.80 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, November 6th will be paid a dividend of $0.38 per share. The ex-dividend date is Thursday, November 5th. This represents a $1.52 annualized dividend and a yield of 4.01%. Pfizer’s payout ratio is currently 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: How to Use a Moving Average for Trading
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.